Education and Training
Dexamethasone Therapy in VLBW Infants at Risk of CLD
Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Dexamethasone Early
- drug: Dexamethasone Late
Eligibility
Inclusion criteria:
- 501 to 1500 grams
- 13 to 15 days old
- Respiratory-index score of greater than or equal to 2.4 that had been increasing or
minimally decreasing during the previous 48 hours or a score of greater than or equal
to 4.0 even if there had been improvement during the preceding 48 hours
Exclusion criteria:
- Received glucocorticoid treatment after birth
- Had evidence or suspicious signs of sepsis as judged by the treating physician
- Major congenital anomaly of the cardiovascular, pulmonary, or central nervous system
Ages Eligible for Study
13 Days - 15 Days
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Not Recruiting